Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
- Therapeutic Areas
Our expertise in the industry
October, worldwide, is designated as the Breast cancer awareness month. Pink ribbons. Pink colored tee-shirts. Pink banners. Going pink, wearing pink - the whole month is devoted to raising awaren...
AZ, Daiichi put their trust into TROP2-based drugs, inks an oncology deal to together develop and commercialize DS-1062AstraZeneca has inked an oncology deal with Daiichi Sankyo to jointly de...
HR-positive/HER2-negative breast cancer treatment landscape focuses on the complexity of the specific cancer type and the treatment differ according to the biomarker status. The trend suggests a g...
Zogenix pays USD 250M upfront Modis clinical drugZogenix, a pharmaceutical company focused on advancing rare disease therapies, has collaborated with the Modis therapeutics. Modis Therapeutic...
Gordon and Betty Moore Foundation gives USD 85 Million to stop delayed, erroneous diagnosticsThe Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation fo...
[caption id="attachment_3465" align="alignnone" width="800"] INSIGHTS ON TRIPLE NEGATIVE BREAST CANCER[/caption] To know more about TRIPLE NEGATIVE BREAST CANCER request for sample pag...
Merck sells biosimilars business to Fresenius Merck has divested its biosimilars business to fellow German drug maker Fresenius in a deal potentially worth 670 million euros. The drug maker said th...
Progress is driven by innovation. When it comes to developing novel medications and the...
The HIV-1 treatment market for naïve and experienced patients is evolving consistently....
The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...
Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...
Advances in genetics research have sparked a surge in interest in gene therapy in derma...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
